You are here

Nexavar

In surprising flop, Exelixis' Cabometyx combo with Roche's Tecentriq fails to extend life in liver cancer

In surprising flop, Exelixis' Cabometyx combo with Roche's Tecentriq fails to extend life in liver cancer

Fierce Pharma

Flag link:

Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer

Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer

Endpoints

clinical trials

Flag link:

Roche's Tecentriq scores a first-in-class double win in new liver cancer patients

Roche's Tecentriq scores a first-in-class double win in new liver cancer patients

Fierce Pharma

immuno-oncology

Flag link:

Bristol-Myers star Opdivo fails survival test in a matchup with Nexavar aimed at shaking up the big HCC market

Bristol-Myers star Opdivo fails survival test in a matchup with Nexavar aimed at shaking up the big HCC market

Endpoints

Bristol-Myers Squibb

clinical trials

Flag link:

Two weeks after Trump unveiled plan to lower drug prices, two cancer drugs got a $1,000-per-month price hike

Two weeks after Trump unveiled plan to lower drug prices, two cancer drugs got a $1,000-per-month price hike

Washington Post, DC

Flag link:

Eisai's Lenvima nabs survival edge in liver cancer showdown with Bayer's Nexavar

Eisai's Lenvima nabs survival edge in liver cancer showdown with Bayer's Nexavar

Fierce Pharma

Flag link:

As U.S. rep eyes global IP, India lets local pharmas export copies of on-patent Bayer blockbusters

As U.S. rep eyes global IP, India lets local pharmas export copies of on-patent Bayer blockbusters

Fierce Pharma

intellectual property

Flag link:

Bayer growth hope Stivarga boosts survival in liver cancer patients

Bayer growth hope Stivarga boosts survival in liver cancer patients

Fierce Pharma

hepatocellular carcinoma

Flag link:

Can Eisai pump its thyroid cancer pill to $1B in sales? Rival Bayer might object

Can Eisai pump its thyroid cancer pill to $1B in sales? Rival Bayer might object

Fierce Pharma Marketing

Flag link:

Bayer loses bid to block cheap version of cancer drug in India

Bayer loses bid to block cheap version of cancer drug in India

FT.com

Flag link:

Bayer, Onyx Pharma Say Phase 3 Trial Of NEXAVAR Fails To Meet Primary Endpoint

Bayer, Onyx Pharma Say Phase 3 Trial Of NEXAVAR Fails To Meet Primary Endpoint

RTT News

ONYX Pharmaceuticals

Flag link:

Cancer drugs from J&J, Roche, Celgene and more rival last big oncology wave

Cancer drugs from J&J, Roche, Celgene and more rival last big oncology wave

Fierce Pharma Marketing

Flag link:

EU agency backs GSK melanoma drug, wider use of Bayer's Nexavar

EU agency backs GSK melanoma drug, wider use of Bayer's Nexavar

Yahoo/Reuters

Flag link:

Bayer, Onyx Report Primary Endpoint of Phase 3 Study Results of NEXAVAR as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation was Not Met

Bayer, Onyx Report Primary Endpoint of Phase 3 Study Results of NEXAVAR as Adjuvant Treatment for Patients with Liver Cancer Who Have Undergone Surgery or Local Ablation was Not Met

Bloomberg

ONYX Pharmaceuticals

Flag link:

U.S. FDA Approves NEXAVAR (sorafenib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment

U.S. FDA Approves NEXAVAR (sorafenib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment

Yahoo/PR NewsWire

ONYX Pharmaceuticals

refractory differential thyroid cancer

Flag link:

Bayer's Nexavar gets priority review as thyroid cancer drug

Bayer's Nexavar gets priority review as thyroid cancer drug

Reuters

Flag link:

Onyx Jumps After Report Amgen Considers Acquisition

Onyx Jumps After Report Amgen Considers Acquisition

Bloomberg

ONYX Pharmaceuticals

Flag link:

Two Diversified Biotechs to Watch After Impressive ASCO Data

Two Diversified Biotechs to Watch After Impressive ASCO Data

Motley Fool

ONYX Pharmaceuticals

tergenpumatucel-L

NewLink Genetics

Flag link:

Bayer's (and ONYX's) Nexavar shown to delay thyroid cancer by 5 months

Bayer's (and ONYX's) Nexavar shown to delay thyroid cancer by 5 months

Reuters

ONYX Pharmaceuticals

Flag link:

Tackling Cancer: Kidney Cancer's Biggest Current and Upcoming Players

Tackling Cancer: Kidney Cancer's Biggest Current and Upcoming Players

Motley Fool

ONYX Pharmaceuticals

Bristol-Myers Squibb

Flag link:

Pages